Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May;104(5):897-905.
doi: 10.1111/aogs.15096. Epub 2025 Mar 17.

Even low levels of anticardiolipin antibodies are associated with pregnancy-related complications: A monocentric cohort study

Affiliations

Even low levels of anticardiolipin antibodies are associated with pregnancy-related complications: A monocentric cohort study

Veronika Viktoria Matraszek et al. Acta Obstet Gynecol Scand. 2025 May.

Abstract

Introduction: Moderate and high levels of anticardiolipin antibodies (aCL), especially in the setting of the antiphospholipid syndrome, are associated with adverse obstetric outcomes. However, the clinical relevance of low aCL levels (<40 MPL/GPL units) is still a matter of debate. The aim of the study was to evaluate obstetric outcomes in pregnancies with low immunoglobulin M (IgM) and/or immunoglobulin G (IgG) aCL positivity. The association between low aCL positivity and maternal baseline characteristics was also studied.

Material and methods: The retrospective monocentric cohort study of prospectively collected data involved a total 3047 singleton pregnancies that underwent the first-trimester screening involving an aCL test and delivered on site. Obstetric outcomes were compared between the low-titer aCL group (IgM ≥7 MPL units and <40 MPL units and/or IgG ≥10 GPL units and <40 GPL units) and the aCL negative group (IgM <7 MPL units and IgG <10 GPL units, reference group). In addition, obstetric outcomes were evaluated with regard to the antibody isotype: IgM-positive group (IgM <40 MPL units, IgG negative) and IgG-positive group (IgG <40 GPL units, IgM negative or <40 MPL units).

Results: Overall, the occurrence of pregnancy-related complications was significantly higher (27.91% vs. 19.32%, p = 0.034) in the low-titer aCL group. Concerning the antibody isotype, a higher rate of pregnancy-related complications was observed in the IgG-positive group (54.55% vs. 19.32%, p = 0.001), but not in the IgM-positive group (22.43% vs. 19.32%, p = 0.454). The stillbirth rate did not reach statistical significance. Low-titer aCL pregnancies were more frequently of advanced maternal age (p < 0.001), suffered from autoimmune diseases (p < 0.001), chronic hypertension (p = 0.040), and hereditary thrombophilia (p = 0.040). In addition, they had more often a positive history of stillbirth (p < 0.001), underwent conception via assisted reproductive technologies (p < 0.001), were administered low-dose aspirin (p < 0.001), low-molecular-weight heparin (p = 0.018) and immunomodulatory drugs (p < 0.001), and delivered earlier (p = 0.018).

Conclusions: Even low aCL levels are associated with a higher incidence of pregnancy-related complications, but only in the case of IgG antibody isotype presence. Screening for aCL in the first trimester has some prognostic value, but further studies are needed to determine whether its potential implementation into routine clinical practice would improve antenatal care.

Keywords: anticardiolipin antibodies; first‐trimester screening; pregnancy‐related complications; stillbirth.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Similar articles

References

    1. Öztürk MA, Haznedaroğlu IC, Turgut M, Göker H. Current debates in antiphospholipid syndrome: the acquired antibody‐mediated thrombophilia. Clin Appl Thromb Hemost. 2004;10:89‐126. - PubMed
    1. El Hasbani G, Viola M, Sciascia S, Taher AT, Uthman I. Antiphospholipid antibodies in inflammatory and autoimmune rheumatic and musculoskeletal diseases beyond lupus: a systematic review of the available evidence. Rheumatol Ther. 2021;8:81‐94. - PMC - PubMed
    1. Reinstein E, Shoenfeld Y. Antiphospholipid syndrome and cancer. Clin Rev Allergy Immunol. 2007;32:184‐187. - PubMed
    1. Asherson RA, Cervera R. Antiphospholipid antibodies and infections. Ann Rheum Dis. 2003;62:388‐393. - PMC - PubMed
    1. Di Prima FA, Valenti O, Hyseni E, et al. Antiphospholipid syndrome during pregnancy: the state of the art. J Prenat Med. 2011;5:41‐53. - PMC - PubMed